ATTENTION: HEALTH RISK WARNING
Depo-Provera, a popular injectable contraceptive, is now under scrutiny for its serious health risks and the failure of its manufacturers to provide adequate warnings. Around 24.5% of all sexually active women in the U.S. have used Depo-Provera at some point, putting a significant number of Americans at risk. While effective at preventing pregnancy, studies show prolonged use may elevate the risk of life-altering conditions like meningiomas, brain cysts, and brain tumors. In fact, women using Depo-Provera are 500% more likely to develop meningiomas, according to The BMJ.
This lack of transparency raises critical questions about accountability in pharmaceutical practices and puts countless users at unnecessary risk.
Potential Health Risks of Depo-Provera:
Bone Mineral Density Loss
Breast Cancer Risk
Brain Tumors (Meningiomas)
Cardiovascular Issues
Allergic Reactions
Delayed Return to Fertility
Depo-Provera brain tumor symptoms may include:
Vision Issue (blurred, double and loss)
Memory loss or Confusion
Seizures
Loss of smell
Weakness in the arms or legs
Trouble speaking
Hold Big Pharma Accountable:
The makers of Depo-Provera have prioritized profits over safety, leaving users to suffer the consequences. Depo-Provera lawsuits against Pfizer Inc. claim the company didn’t warn patients about the risk of brain tumors associated with this medication. There are currently over 100 lawsuits pending against Pfizer related to Depo-Provera and brain tumors. If you or a loved one have been diagnosed with a Meningioma Tumor after using Depo-Provera for at least one year, it’s time to take a stand. Litigation Notification is here to empower you to fight back and pursue the justice and compensation you deserve.
Why Act Now?
Settlements for cases like these can range from $50,000 to over $1 million, depending on the severity of injuries. However, state laws limit the time you have to file a claim under statutes of limitations. Don’t miss your chance to seek accountability and protect others from harm.